Laboratory Corp. of America Holdings (NYSE:LH) a Buy: Maxim Group

In a research note issued to investors, Bryan Brokmeier at Maxim Group Reiterated their Buy rating on Laboratory Corp. of America Holdings (NYSE:LH). The analyst placed a $160.00 price target on the stock which indicates a 25.84% upside to the last closing price. In the year following Brokmeier’s ratings, the stocks covered yield an average return of -2.90% according to TipRanks.com. In the past year 13 out of 27 recommendations or 48% were successful.

Wall Street analysts have placed a target price of $138.437 for Laboratory Corporation of America Holdings (NYSE:LH). This number is based on the mean consensus estimate from the 16 research firms that recently issued reports on the stock.

The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 is a Strong Buy and 5 is a Strong Sell, has the stock ranked 1.61 based on 16 broker recommendations. Of the 16 analysts who have issued estimates, the most bullish sees the stock reaching $165 within the next 12 months while the most conservative sees the stock at $108 within the year.

According to analysts, Laboratory Corporation of America Holdings (NYSE:LH) is expected to report earnings per share for the current fiscal quarter of $1.65. This is the consensus mean estimate based on the individual covering sell-side analysts\’ reported numbers. The company last reported earnings for the period ending on 2014-12-31 of $1.65. The reported number was 0.02 away from the consensus estimate, or a surprise factor of 1.23 .

In looking at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $7.59. The high end estimate for this time frame is $8.06 with the low being $7.05.

Laboratory Corporation of America Holdings is a clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of testing services used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. In addition, it has developed specialty and niche operations based on certain types of specialized testing capabilities and client requirements, such as oncology testing, human immunodeficiency virus (HIV) genotyping and phenotyping, diagnostic genetics and clinical research trials. It processes tests on approximately 470,000 patient specimens daily and provides clinical laboratory testing services in all 50 states, the District of Columbia, Puerto Rico, Belgium, Japan, the United Kingdom, China, Singapore and three provinces in Canada.